Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6357-6362

  Ross, Jeffrey S ^a,c   Sheehan, Christine E ^a   Fisher, Hugh A G ^a   Kaufman Jr , Ronald P ^a   Kaur, Prabhjot ^a   Gray, Karen ^c   Webb, Iain ^c   Gray, Gary S ^c   Mosher, Rebecca ^c   Kallakury, Bhaskar V S ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ANTIGEN EXPRESSION; ARTICLE; AUTORADIOGRAPHY; BENIGN TUMOR; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEULGEN STAINING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; AUTORADIOGRAPHY; CYTOPLASM; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENCE; RNA, MESSENGER; TIME FACTORS;

EID: 0346333234     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R., and Heston, W. D. Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807-1811, 1994.
2. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L., and Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 160: 2396-2401, 1998.
3. Tasch, J., Gong, M., Sadelain, M., and Heston, W. D. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol., 21: 249-261, 2001.
4. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D., and Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 3: 81-85, 1997.
5. Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., and Holmes, E. H. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (Phila.), 83: 2259-2269, 1998.
6. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., and Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (Phila.), 82: 2256-2261, 1998.
7. Lapidus, R. G., Tiffany, C. W., Isaacs, J. T., and Slusher, B. S. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate, 45: 350-354, 2000.
8. Sweat, S. D., Pacelli, A., Murphy, G. P., and Bostwick, D. G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 52: 637-640, 1998.
9. Chang, S. S., Reuter, V. E., Heston, W. D., and Gaudin, P. B. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology, 57: 1179-1183, 2001.
10. Murphy, G. P., Maguire, R. T., Rogers, B., Partin, A. W., Nelp, W. B., Troychak, M. J., Ragde, H., Kenny, G. M., Barren, R. J., III, Bowes. V. A., Gregorakis, A. K., Holmes, E. H., and Boynton, A. L. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate, 33: 281-285, 1997.
11. Yao, D., Trabulsi, E. J., Kostakoglu, L., Vallabhajosula, S., Joyce, M. A., Nanus, D. M., Milowsky, M., Liu, H., and Goldsmith, S. J. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin. Urol. Oncol., 20: 211-218, 2002.
12. Gong, M. C., Chang, S. S., Sadelain, M., Bander, N. H., and Heston, W. D. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev., 18: 483-490, 1999.
13. Gong, M. C., Chang, S. S., Watt, F., O'Keefe, D. S., Bacich, D. J., Uchida, A., Bander, N. H., Reuter, V. E., Gaudin, P. B., Molloy, P. L., Sadelian, M., and Heston, W. D. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol. Urol., 4: 217-222, 2000.
14. Holmes, E. H. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Investig. Drugs, 10: 511-519, 2001.
15. Wright, G. L., Jr., Grob, B. M., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., and Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326-334, 1996.
16. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3534, 1997.
17. Chang, S. S., O'Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D., and Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res., 5: 2674-2681, 1999.
18. Chang, S. S., Reuter, V. E., Heston, W. D., Bander, N. H., Grauer, L. S., and Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res., 59: 3192-3198, 1999.
19. Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol., 23: 273-279, 1992.
20. Ohori, M., Wheeler, T. M., and Scardino, P. T. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer (Phila.), 74: 104-114, 1994.
21. Ross, J. S., Sheehan, C. E., Ambros, R. A., Nazeer, T., Jennings, T. A., Kaufman, R. P., Jr., Fisher, H. A. G., Rifkin, M. D., and Kallakury, B. V. S. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am. J. Surg. Pathol., 23: 296-301, 1999.
22. Isaacs, J. T. Molecular markers for prostate cancer metastasis. Am. J. Pathol., 150: 1511-1521, 1997.
23. Bostwick, D. G., Grignon, D. J., Hammond, M. E., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montriona, R., Pajak, T. F., Pollack, A., Srigley, J. R., and Yarbro, J. W. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med., 124: 995-1000, 2000.
24. Koch, M. O., Foster, R. S., Bell, B., Beck, S., Cheng, L., Parekh, D., and Jung, S. H. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J. Urol., 164: 749-753, 2000.
25. Alers, J. C., Rochat, J., Krijtenburg, P. J., Hop, W. C., Kranse, R., Rosenberg, C., Tanke, H. J., Schroder, F. H., and van Dekken, H. Identification of genetic markers for prostatic cancer progression. Lab. Investig., 80: 931-942, 2000.
26. Ross, J. S., Sheehan, C. E., Fisher, H. A. G., Kauffman, R. A., Jr., Dolen, E. M., and Kallakury, B. V. S. Prognostic markers in prostate cancer. Expert Rev. Mol. Diagn., 2: 129-142, 2002.
27. Stattin, P. Prognostic factors in prostate cancer. Scand. J. Urol. Nephrol. Suppl., 185: 1-46, 1997.
28. Catalona, W. J., Ramos, C. G., and Carvalhal, G. F. Contemporary results of anatomic radical prostatectomy. CA Cancer J. Clin., 49: 282-296, 1999.
29. Peters-Gee, J. M., Miles, B. J., Cerny, J. C., Gaba, A. R., Jacobsen, G., and Crissman, J. D. Prognostic significance of DNA quantification in stage D1 prostatic carcinoma with the use of image analysis. Cancer (Phila.), 70: 1159-1165, 1992.
30. Montgomery, B. T., Nativ, O., Blute, M., Farrow, G. M., Myers, R. P., Zincke, H., Therneau, T. M., and Lieber, M. M. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch. Surg., 125: 327-331, 1990.
31. Ross, J. S., Figge, H., Bui, H. X., del Rosario, A. D., Jennings, T. A., Rifkin, M. D., and Fisher, H. A. G. Prediction of pathologic stage and post prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer (Phila.), 74: 2811-2818, 1994.
32. Troyer, J. K., Beckett, M. L., and Wright, G. L., Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 30: 232-242, 1997.
33. Barren, R. J., III, Holmes, E. H., Boynton, A. L., Misrock, S. L., and Murphy, G. P. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate, 30: 65-68, 1997.
34. 111In capromab pendetide (Prosta-Scint®) immunoscintigraphy in the management of prostate cancer. Q. J. Nucl. Med., 46: 131-137, 2002.
35. Elgamal, A. A., Troychak, M. J., and Murphy, G. P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate, 37: 261-269, 1998.